Kos pharmaceuticals acquired the US sales and marketing rights to the long-acting antihypertensive agent Cardizem® LA from Biovail for US$104 M. As part of the multi-faceted deal Biovail also sold the Teveten® line of angiotensin receptor II blockers to Kos.